# Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

> **NCT02968004** · PHASE3 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 224 (actual)

## Conditions studied

- Pediatric Growth Hormone Deficiency

## Interventions

- **DRUG:** MOD-4023
- **DRUG:** Somatropin

## Key facts

- **NCT ID:** NCT02968004
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2019-08
- **Final completion:** 2024-05
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968004, "Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02968004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*